Missouri Clinical Trials Report — June 2026

For Missourians considering participation in clinical research, June 2026 presents both urgent opportunities and a significant expansion of new studies. Across the state, 103 clinical trials are scheduled to conclude within the next 90 days, creating a critical window for enrollment. This includes 20 studies actively seeking healthy volunteers, offering a chance to contribute to medical advancements without a specific health condition.

Individuals living with certain health conditions should also act quickly to explore trials with impending deadlines. Research focusing on various conditions, including specific cancer types and cardiovascular health, are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Neoplasms by histologic type
• Venous leg ulcer
• Healthy participants
• Multiple myeloma
• Quality of life studies
• Vasodilation research
• Endometrial cancer
• Fallopian tube cancer
• Heart failure
• Lupus nephritis

Major Research Initiatives Launch Across Missouri

This month, Missouri welcomes 38 new clinical trials, a notable increase from the 23 trials that opened in May 2026. These new studies include several significant Phase 3 drug trials from major pharmaceutical companies, offering participants access to cutting-edge treatments for widespread health challenges like obesity, type 2 diabetes, and migraine.

• AstraZeneca is sponsoring NCT07667803, a Phase 3 "Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM." This substantial global study aims to enroll 4,500 participants, evaluating a new treatment for weight management and type 2 diabetes.
• Another major Phase 3 trial, NCT07654361, is "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)," sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. This global study seeks 3,600 participants to assess the long-term efficacy and safety of aleniglipron for weight management.
• For those experiencing migraines, Kallyope Inc. is leading two important Phase 3 trials. NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine," aims for 1,800 participants. Additionally, NCT07674654 is a long-term safety study for the same drug, planning for 1,000 participants.
• AstraZeneca is also sponsoring two further Phase 3 studies focused on type 2 diabetes mellitus. NCT07662213, "A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide," will enroll 1,200 participants. Another study, NCT07662135, investigates elecoglipron in 900 adults with type 2 diabetes and impaired renal function.
• Gasherbrum Bio, Inc. also has NCT07654374, "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)," a Phase 3 trial targeting 1,100 participants.
• A significant, long-term study, NCT07625579, "Collaboration for Down Syndrome Progress (CDP)," sponsored by RTI International, plans to enroll 1,400 participants to better understand the health and development of people with Down syndrome of all ages.

Expanding Research Across Diverse Health Conditions

The 38 new trials opening this month in Missouri cover a diverse range of health conditions, with a strong focus on metabolic health. The most common conditions addressed by these new studies include:

• Obesity (5 trials)
• Overweight (4 trials)
• Type 2 diabetes mellitus (3 trials)
• Chronic pain (2 trials)
• Chronic weight management (2 trials)

Beyond these, new research is also exploring areas such as attention, anterior cruciate ligament reconstruction rehabilitation, advanced breast cancer, cervical disease, and the effects of caffeine. In terms of intervention types, drug trials lead the way, accounting for 27 of the new studies. Behavioral interventions contribute 3 new trials, while device and biological studies each add 4 and 2 new opportunities, respectively. Dietary supplement and procedure trials also offer new avenues for participation.

Academic institutions continue to play a vital role in the state's research ecosystem, with Washington University School of Medicine sponsoring 8 of the new trials and the University of Missouri-Columbia sponsoring 2. Industry sponsors are also driving significant research efforts, with 20 new trials sponsored by pharmaceutical companies such as AstraZeneca, Eli Lilly and Company, Gasherbrum Bio, Inc., Novo Nordisk A/S, and Kallyope Inc.

Missouri's Research Footprint: Opportunities Across the State

Missouri's clinical research landscape is robust, with 1,858 clinical trials currently recruiting across 63 cities and 942 research sites statewide. This month, the majority of new research initiatives are concentrated in the state's major metropolitan areas, ensuring broad access for many residents. The cities with the most new trials include:

• St Louis (24 new trials)
• Kansas City (9 new trials)
• Springfield (7 new trials)
• City of Saint Peters (7 new trials)
• Hazelwood (4 new trials)
• Chesterfield (2 new trials)
• Columbia (2 new trials)

Additionally, North Kansas City and Jefferson City each welcomed 1 new trial, demonstrating that research opportunities are available beyond the largest urban centers. This distribution ensures that residents in various regions of Missouri have access to cutting-edge research, from major university medical centers to community-based sites.

Healthy Volunteers and Diverse Demographics in Focus

For individuals without a specific medical condition, there are significant opportunities to contribute to medical science. Of the 38 new trials launched this month, 6 are actively seeking healthy volunteers. Statewide, a total of 190 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Clinical trials in Missouri are designed to be inclusive, with a broad range of eligibility criteria. Of the new trials, 4 include children as participants, and a substantial 34 include older adults, ensuring that research benefits diverse age groups. While most trials are open to both sexes, 1 new trial is female-only and 2 are male-only, addressing specific health questions relevant to these populations.

As we move through June, the focus will remain on the ongoing enrollment in these significant Phase 3 trials and the exploration of new treatments, diagnostics, and preventive measures for a broad spectrum of health challenges across Missouri. We encourage interested individuals to explore these opportunities promptly, especially those with approaching enrollment deadlines.